中国P站

Pharmacognosy; Indigenous medicinal plants; Antimicrobial activity; Ethnobotany; Phytochemicals; Plant-based antibiotics; Secondary metabolites; Antimicrobial resistance; Herbal medicine; Bioactive compounds; Traditional knowledge; Extraction methods; Alkaloids; Flavonoids; Terpenoids; Tannins; MIC; Zone of inhibition; In vitro testing; Plant pharmacology; Drug discovery

Introduction

The growing threat of antimicrobial resistance (AMR) has accelerated the global search for novel and effective antimicrobial agents. With conventional antibiotics becoming less effective, attention has turned toward nature’s pharmacopoeia, particularly indigenous medicinal plants that have been used for centuries in traditional healing systems. Pharmacognosy, the study of drugs derived from natural sources, offers valuable insights into the bioactive compounds found in these plants and their therapeutic potential. Indigenous medicinal flora, rich in structurally diverse secondary metabolites, have shown promising antimicrobial activity against a wide spectrum of pathogens. This article provides a comprehensive pharmacognostic perspective on the antimicrobial properties of indigenous medicinal plants, highlighting their phytochemical composition, mechanisms of action, and relevance in the fight against infectious diseases [1,2].

Description

Indigenous medicinal plants are used extensively in ethnomedical practices across Africa, Asia, the Americas, and Oceania. These plants often serve as primary healthcare resources in rural and traditional communities and are prepared in various forms such as decoctions, tinctures, poultices, and infusions. Scientific interest in these botanicals has grown significantly, leading to the isolation and characterization of numerous antimicrobial phytochemicals [3]. Pharmacognostic evaluation encompasses macroscopic and microscopic identification, phytochemical screening, and biological assays to determine the pharmacological activity of plant extracts. The antimicrobial efficacy of these plants is often attributed to secondary metabolites, including alkaloids, flavonoids, phenolics, saponins, tannins, terpenoids, and essential oils. These compounds exert antibacterial, antifungal, antiviral, and antiparasitic effects through various mechanisms [4].

Common indigenous plants studied for their antimicrobial potential include:

Azadirachta indica (Neem): Contains azadirachtin and nimbidin with broad-spectrum antimicrobial properties.

Ocimum sanctum (Holy Basil): Rich in eugenol and ursolic acid, effective against respiratory and urinary tract pathogens.

Allium sativum (Garlic): Contains allicin, a potent antimicrobial agent disrupting bacterial cell walls.

Curcuma longa (Turmeric): Curcumin demonstrates antimicrobial, anti-inflammatory, and synergistic effects with antibiotics.

Zingiber officinale (Ginger): Shows significant inhibitory effects against Gram-positive and Gram-negative bacteria.

Phytochemical extraction for antimicrobial testing commonly uses solvents such as ethanol, methanol, chloroform, and aqueous solutions. The choice of solvent affects the efficiency of bioactive compound extraction. In vitro techniques like the agar well diffusion method, disk diffusion method, and broth dilution assays are employed to determine the zone of inhibition, minimum inhibitory concentration (MIC), and minimum bactericidal concentration (MBC) [5].

Discussion

The antimicrobial potential of indigenous medicinal plants lies in their biochemical complexity. Alkaloids, for instance, interfere with nucleic acid synthesis and protein translation in microbes. Flavonoids can disrupt membrane integrity and inhibit bacterial virulence factors. Terpenoids and essential oils penetrate microbial membranes, causing leakage of intracellular contents. Tannins precipitate microbial proteins and form complexes with metal ions, making them unavailable for microbial enzymes [6].

One of the most compelling features of plant-based antimicrobials is their multimodal mechanism of action, which reduces the likelihood of resistance development. For example, allicin in garlic reacts with thiol groups of bacterial enzymes, causing functional inactivation. Similarly, curcumin modulates quorum sensing and biofilm formation, rendering bacteria more susceptible to immune clearance or antibiotics. Synergism with antibiotics is another pharmacologically relevant feature. Several studies have shown that combining plant extracts with standard antibiotics enhances their efficacy against multidrug-resistant (MDR) strains. For instance, ethanol extracts of neem or tulsi have potentiated the activity of ciprofloxacin and ampicillin against Staphylococcus aureus and Escherichia coli [7]. Pharmacognostic analysis also involves quality control parameters like ash values, extractive values, moisture content, fluorescence analysis, and chromatographic profiling, which are essential for standardizing plant-based formulations. These parameters ensure batch-to-batch consistency, especially in commercial herbal products .Despite the promise shown in in vitro studies, the translation of these findings into clinically viable drugs faces several challenges [8].

Variability in plant composition due to geographical, seasonal, and harvesting differences. Poor bioavailability of some phytochemicals, like curcumin, which limits systemic antimicrobial effects. Toxicological concerns, particularly with long-term use or high doses of crude extracts. Regulatory hurdles in integrating herbal antimicrobials into modern therapeutic protocols. To overcome these issues, nanoformulation, synergistic combination therapy, and biotechnological enhancements such as plant tissue culture and metabolic engineering are being explored. Furthermore, genome mining and metabolomics have enabled the discovery of novel compounds in traditionally used plants, reinforcing the importance of ethnobotanical knowledge [9].

Field-based ethnobotanical surveys also continue to identify lesser-known indigenous plants with antimicrobial potential. For example, Aegle marmelos, Lawsonia inermis, Andrographis paniculata, and Terminalia chebula have shown strong activity against bacterial and fungal strains associated with skin, gastrointestinal, and respiratory infections. Additionally, indigenous communities provide rich oral traditions and empirical knowledge of plant-based medicine, including preparation methods, dosage, and specific therapeutic uses. Collaborations with these communities, combined with modern pharmacognostic techniques, have the potential to yield novel and safe antimicrobial agents [10].

Conclusion

Indigenous medicinal plants remain a valuable reservoir of antimicrobial agents, supported by both traditional knowledge and modern pharmacognostic research. Their rich phytochemical profiles, especially secondary metabolites like alkaloids, flavonoids, and terpenoids, offer promising mechanisms to combat microbial infections and antibiotic resistance. Through meticulous pharmacognostic evaluation—encompassing identification, standardization, and bioassays—scientists can validate traditional claims and identify lead compounds for drug development.

However, challenges such as bioavailability, toxicity, and standardization must be addressed through innovative approaches and interdisciplinary collaboration. Integration of ethnobotanical wisdom, pharmacognostic methodology, and modern pharmacology will pave the way for novel, plant-derived antimicrobials that are safe, effective, and sustainable. As antimicrobial resistance threatens global health, the exploration of indigenous medicinal flora offers a hopeful and scientifically grounded path forward.

References

1. Kuhlmann L, Lehnertz K, Richardson MP, Schelter B, Zaveri HP (2018) Nat Rev Neurol 14: 618-630.

   , ,

2. Ramgopal S, Thome-Souza S, Jackson M, Kadish NE, Fernandez IS, et al. (2014) Epilepsy Behav 37: 291-307.

   , ,

3. Acharya UR, Vinitha Sree S, Swapna G, Martis RJ, Suri JS (2013) Knowledge-Based Syst 45: 147-165.

   ,

4. Federico P, Abbott DF, Briellmann RS, Harvey AS, Jackson GD (2005) Brain 128: 1811-1817.

   , ,

5. Suzuki Y, Miyajima M, Ohta K, Yoshida N, Okumura M, et al. (2015) J ECT 31: 186-191.

   , ,

6. Mormann F, Kreuz T, Rieke C, Andrzejak RG, Kraskovet A, et al. (2005) Clin Neurophysiol 116: 569-587.

   , ,

7. Bandarabadi M, Rasekhi J, Teixeira CA, Karami MR, Dourado A (2015) Epilepsy Behav 46: 158-166.

   , ,

8. Valderrama M, Alvarado C, Nikolopoulos S, Martinerie J, Adam C, et al. (2012) Biomed Sign 7: 237-244.

   ,

9. Teixeira CA, Direito B, Bandarabadi M, Le Van Quyen M, Valderrama M, et al. (2014) Comput Methods Programs in Biomed 114: 324-336.

   , ,

10. Direito B, Teixeira CA, Sales F, Castelo-Branco M, Dourado A (2017) Int J Neural Syst 27: 1-15.

    , ,